Form 4: Veru Inc. Executive Michele Greco Acquires Options in Company Stock

Michele Greco, Chief Administrative Officer and CFO of Veru Inc., reports the acquisition of options to purchase 106,000 shares of common stock.

Summary

• On May 7, 2024, Michele Greco, the Chief Administrative Officer and CFO of Veru Inc., acquired options to purchase 106,000 shares of Veru Inc. common stock at an exercise price of $1.63.
• The options are an annual award grant for fiscal year 2024.
• One-third of the shares vest annually on May 7, 2025, May 7, 2026, and May 7, 2027.
• The options expire on May 7, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard executive compensation practice. It's neither overwhelmingly positive nor negative.

Positives

• The grant of options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans to incentivize performance and align executive interests with shareholder value.

Stakeholder Impact

• The option grant could positively impact shareholders if it incentivizes the executive to improve company performance.
• Employees may view the option grant as a positive sign of the company's commitment to its leadership.

Key Dates